Target Name: MKI67
NCBI ID: G4288
Review Report on MKI67 Target / Biomarker Content of Review Report on MKI67 Target / Biomarker
MKI67
Other Name(s): antigen identified by monoclonal antibody Ki-67 | KI67 | MIB-1 | OTTHUMP00000020739 | PPP1R105 | Proliferation marker protein Ki-67 | Antigen Ki67 | marker of proliferation Ki-67 | MKI67 variant 2 | KI67_HUMAN | MIB- | Antigen KI-67 | Proliferation marker protein Ki-67 (isoform 2) | Marker of proliferation Ki-67, transcript variant 1 | KIA | OTTHUMP00000020740 | proliferation-related Ki-67 antigen | Proliferation-related Ki-67 antigen | Ki-67 | MKI67 variant 1 | Antigen identified by monoclonal antibody Ki-67 | protein phosphatase 1, regulatory subunit 105 | antigen Ki67 | Proliferation marker protein Ki-67 (isoform 1) | Molecular Immunology Borstel antibody 1 | Marker of proliferation Ki-67, transcript variant 2

Monoclonal Antibody Ki-67 as a Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Abstract:

Inflammatory diseases have a significant impact on human health, causing chronic pain, disability, and even death. One of the leading causes of inflammatory diseases is chronic myeloid leukemia (CML), a type of cancer that affects the bone marrow and blood cells. The treatment of CML is often limited to chemotherapy, radiation therapy, and bone marrow transplantation, which can be life-threatening. To address this, there is a growing interest in finding new treatments and biomarkers for the treatment of inflammatory diseases. In this article, we discuss the monoclonal antibody Ki-67 as a potential drug target and biomarker for the treatment of inflammatory diseases, including CML.

Introduction:

Inflammatory diseases are a leading cause of morbidity and mortality, causing significant economic burden. These diseases include chronic obstructive pulmonary disease (COPD), autoimmune diseases such as rheumatoid arthritis (RA), and inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. The treatment of inflammatory diseases is often limited to immunomodulatory drugs, which can have significant side effects.

Monoclonal antibodies ( antibodies are a group of proteins produced by the immune system that help to neutralize foreign substances like viruses and bacteria) have emerged as a promising new class of treatments for inflammatory diseases. These antibodies are produced in large quantities by the immune system and can be directed against specific molecules, such as bacteria, viruses, and cancer cells. By using antibodies to target and neutralize inflammation, researchers hope to find new treatments for inflammatory diseases.

Ki-67 as an Antigen and Potential Drug Target:

Ki-67 is a monoclonal antibody that has been shown to be effective in treating various inflammatory diseases, including CML. Ki-67 is directed against the BCR-Abl protein, which is a key regulator of the B cell lineage and is expressed in a variety of tissues, including the bone marrow, where it is present in high levels.

Studies have shown that Ki-67 can effectively target and neutralize BCR-Abl-expressing cells, including those derived from CML. Ki-67 has been shown to improve the response to chemotherapy in patients with CML and can also be used in combination with chemotherapy to treat the disease.

In addition to its potential use as a cancer treatment, Ki-67 has also been shown to have potential as a biomarker for the diagnosis and monitoring of various inflammatory diseases. Ki-67 levels have been shown to be elevated in the blood and other tissues in patients with a variety of inflammatory diseases, including CML, RA, and inflammatory bowel diseases.

Ki-67 as a Biomarker:

The detection and quantification of biomarkers is an important aspect of the diagnosis and treatment of inflammatory diseases. Ki-67 has been shown to be a potential biomarker for the treatment of inflammatory diseases due to its ability to be detected and quantified in various tissues and fluids, including blood, urine, and bone marrow.

Studies have shown that Ki-67 levels can be used as a marker for the diagnosis and monitoring of inflammatory diseases, including CML. Researchers have found that Ki-67 levels are elevated in the blood and other tissues in patients with CML, and that these levels can be used to predict the response to chemotherapy.

In addition to its potential use as a cancer biomarker, Ki-67 has also been shown to have potential as a biomarker for other inflammatory diseases, including RA and inflammatory bowel diseases. Ki-67 levels have been shown to be elevated in the blood and other tissues in patients with these conditions, and that these levels can be used to monitor the response to treatment.

Conclusion:

In conclusion, Ki-67 is a monoclonal antibody that has been shown to be effective in treating various inflammatory diseases, including CML. Ki-67 is also potential as a biomarker for the diagnosis and monitoring of these diseases. Further research is needed to fully understand the potential of Ki-67 as a new drug target and biomarker for the treatment of inflammatory diseases.

Protein Name: Marker Of Proliferation Ki-67

Functions: Required to maintain individual mitotic chromosomes dispersed in the cytoplasm following nuclear envelope disassembly (PubMed:27362226). Associates with the surface of the mitotic chromosome, the perichromosomal layer, and covers a substantial fraction of the chromosome surface (PubMed:27362226). Prevents chromosomes from collapsing into a single chromatin mass by forming a steric and electrostatic charge barrier: the protein has a high net electrical charge and acts as a surfactant, dispersing chromosomes and enabling independent chromosome motility (PubMed:27362226). Binds DNA, with a preference for supercoiled DNA and AT-rich DNA (PubMed:10878551). Does not contribute to the internal structure of mitotic chromosomes (By similarity). May play a role in chromatin organization (PubMed:24867636). It is however unclear whether it plays a direct role in chromatin organization or whether it is an indirect consequence of its function in maintaining mitotic chromosomes dispersed (Probable)

The "MKI67 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MKI67 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MKKS | MKLN1 | MKLN1-AS | MKNK1 | MKNK1-AS1 | MKNK2 | MKRN1 | MKRN2 | MKRN2OS | MKRN3 | MKRN4P | MKRN7P | MKRN9P | MKS1 | MKX | MLANA | MLC1 | MLEC | MLF1 | MLF1-DT | MLF2 | MLH1 | MLH3 | MLIP | MLIP-AS1 | MLKL | MLLT1 | MLLT10 | MLLT10P1 | MLLT11 | MLLT3 | MLLT6 | MLN | MLNR | MLPH | MLST8 | MLX | MLXIP | MLXIPL | MLYCD | MMAA | MMAB | MMACHC | MMADHC | MMADHC-DT | MMD | MMD2 | MME | MMEL1 | MMGT1 | MMP | MMP1 | MMP10 | MMP11 | MMP12 | MMP13 | MMP14 | MMP15 | MMP16 | MMP17 | MMP19 | MMP2 | MMP2-AS1 | MMP20 | MMP20-AS1 | MMP21 | MMP23A | MMP23B | MMP24 | MMP24-AS1-EDEM2 | MMP24OS | MMP25 | MMP25-AS1 | MMP26 | MMP27 | MMP28 | MMP3 | MMP7 | MMP8 | MMP9 | MMRN1 | MMRN2 | MMS19 | MMS22L | MMS22L-TONSL complex | MMUT | MMXD complex | MN1 | MNAT1 | MND1 | MNDA | MNS1 | MNT | MNX1 | MNX1-AS1 | MOAP1 | MOB1A | MOB1B | MOB2 | MOB3A